Standard

Dose-dependent suppression of human glioblastoma xenograft growth by accelerator-based boron neutron capture therapy with simultaneous use of two boron-containing compounds. / Kanygin, Vladimir; Razumov, Ivan; Zaboronok, Alexander и др.

в: Biology, Том 10, № 11, 1124, 11.2021.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

Kanygin, V, Razumov, I, Zaboronok, A, Zavjalov, E, Kichigin, A, Solovieva, O, Tsygankova, A, Guselnikova, T, Kasatov, D, Sycheva, T, Mathis, BJ & Taskaev, S 2021, 'Dose-dependent suppression of human glioblastoma xenograft growth by accelerator-based boron neutron capture therapy with simultaneous use of two boron-containing compounds', Biology, Том. 10, № 11, 1124. https://doi.org/10.3390/biology10111124

APA

Kanygin, V., Razumov, I., Zaboronok, A., Zavjalov, E., Kichigin, A., Solovieva, O., Tsygankova, A., Guselnikova, T., Kasatov, D., Sycheva, T., Mathis, B. J., & Taskaev, S. (2021). Dose-dependent suppression of human glioblastoma xenograft growth by accelerator-based boron neutron capture therapy with simultaneous use of two boron-containing compounds. Biology, 10(11), [1124]. https://doi.org/10.3390/biology10111124

Vancouver

Kanygin V, Razumov I, Zaboronok A, Zavjalov E, Kichigin A, Solovieva O и др. Dose-dependent suppression of human glioblastoma xenograft growth by accelerator-based boron neutron capture therapy with simultaneous use of two boron-containing compounds. Biology. 2021 нояб.;10(11):1124. doi: 10.3390/biology10111124

Author

Kanygin, Vladimir ; Razumov, Ivan ; Zaboronok, Alexander и др. / Dose-dependent suppression of human glioblastoma xenograft growth by accelerator-based boron neutron capture therapy with simultaneous use of two boron-containing compounds. в: Biology. 2021 ; Том 10, № 11.

BibTeX

@article{f1f2e43bea104fcfaba340343b5e51c7,
title = "Dose-dependent suppression of human glioblastoma xenograft growth by accelerator-based boron neutron capture therapy with simultaneous use of two boron-containing compounds",
abstract = "(1) Background: Developments in accelerator-based neutron sources moved boron neutron capture therapy (BNCT) to the next phase, where new neutron radiation parameters had to be studied for the treatment of cancers, including brain tumors. We aimed to further improve accelerator-BNCT efficacy by optimizing dosimetry control, beam parameters, and combinations of boronophenylalanine (BPA) and sodium borocaptate (BSH) administration in U87MG xenograftbearing immunodeficient mice with two different tumor locations. (2) Methods: The study included two sets of experiments. In Experiment #1, BPA only and single or double irradiation in higher doses were used, while, in Experiment #2, BPA and BSH combinations and single or double irradiation with dosage adjustment were analyzed. Mice without treatment or irradiation after BPA or BPA+BSH injection were used as controls. (3) Results: Irradiation parameter adjustment and BPA and BSH combination led to 80–83% tumor-growth inhibition index scores, irradiation:BNCT ratios of 1:2, and increases in animal life expectancy from 9 to 107 days. (4) Conclusions: Adjustments in dosimetry control, calculation of irradiation doses, and combined use of two10B compounds allowed for BNCT optimization that will be useful in the development of clinical-trial protocols for accelerator-based BNCT.",
keywords = "Accelerator-based neutron source, Animal tumor model, Boron compounds, Boron neutron capture therapy, Boronophenylalanine, Glioblastoma, Sodium borocaptate",
author = "Vladimir Kanygin and Ivan Razumov and Alexander Zaboronok and Evgenii Zavjalov and Aleksandr Kichigin and Olga Solovieva and Alphiya Tsygankova and Tatiana Guselnikova and Dmitrii Kasatov and Tatiana Sycheva and Mathis, {Bryan J.} and Sergey Taskaev",
note = "Funding Information: Funding: The research was supported by the RUSSIAN FOUNDATION FOR BASIC RESEARCH, scientific project No. 18-29-01007. The research related to quantitative chemical analysis of organs and tissues was supported by the MINISTRY OF SCIENCE AND HIGHER EDUCATION OF THE RUSSIAN FEDERATION, project No. 121031700315-2. The neutron generation study was supported by the RUSSIAN SCIENCE FOUNDATION, project No. 19-72-30005. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2021",
month = nov,
doi = "10.3390/biology10111124",
language = "English",
volume = "10",
journal = "Biology",
issn = "2079-7737",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

RIS

TY - JOUR

T1 - Dose-dependent suppression of human glioblastoma xenograft growth by accelerator-based boron neutron capture therapy with simultaneous use of two boron-containing compounds

AU - Kanygin, Vladimir

AU - Razumov, Ivan

AU - Zaboronok, Alexander

AU - Zavjalov, Evgenii

AU - Kichigin, Aleksandr

AU - Solovieva, Olga

AU - Tsygankova, Alphiya

AU - Guselnikova, Tatiana

AU - Kasatov, Dmitrii

AU - Sycheva, Tatiana

AU - Mathis, Bryan J.

AU - Taskaev, Sergey

N1 - Funding Information: Funding: The research was supported by the RUSSIAN FOUNDATION FOR BASIC RESEARCH, scientific project No. 18-29-01007. The research related to quantitative chemical analysis of organs and tissues was supported by the MINISTRY OF SCIENCE AND HIGHER EDUCATION OF THE RUSSIAN FEDERATION, project No. 121031700315-2. The neutron generation study was supported by the RUSSIAN SCIENCE FOUNDATION, project No. 19-72-30005. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021/11

Y1 - 2021/11

N2 - (1) Background: Developments in accelerator-based neutron sources moved boron neutron capture therapy (BNCT) to the next phase, where new neutron radiation parameters had to be studied for the treatment of cancers, including brain tumors. We aimed to further improve accelerator-BNCT efficacy by optimizing dosimetry control, beam parameters, and combinations of boronophenylalanine (BPA) and sodium borocaptate (BSH) administration in U87MG xenograftbearing immunodeficient mice with two different tumor locations. (2) Methods: The study included two sets of experiments. In Experiment #1, BPA only and single or double irradiation in higher doses were used, while, in Experiment #2, BPA and BSH combinations and single or double irradiation with dosage adjustment were analyzed. Mice without treatment or irradiation after BPA or BPA+BSH injection were used as controls. (3) Results: Irradiation parameter adjustment and BPA and BSH combination led to 80–83% tumor-growth inhibition index scores, irradiation:BNCT ratios of 1:2, and increases in animal life expectancy from 9 to 107 days. (4) Conclusions: Adjustments in dosimetry control, calculation of irradiation doses, and combined use of two10B compounds allowed for BNCT optimization that will be useful in the development of clinical-trial protocols for accelerator-based BNCT.

AB - (1) Background: Developments in accelerator-based neutron sources moved boron neutron capture therapy (BNCT) to the next phase, where new neutron radiation parameters had to be studied for the treatment of cancers, including brain tumors. We aimed to further improve accelerator-BNCT efficacy by optimizing dosimetry control, beam parameters, and combinations of boronophenylalanine (BPA) and sodium borocaptate (BSH) administration in U87MG xenograftbearing immunodeficient mice with two different tumor locations. (2) Methods: The study included two sets of experiments. In Experiment #1, BPA only and single or double irradiation in higher doses were used, while, in Experiment #2, BPA and BSH combinations and single or double irradiation with dosage adjustment were analyzed. Mice without treatment or irradiation after BPA or BPA+BSH injection were used as controls. (3) Results: Irradiation parameter adjustment and BPA and BSH combination led to 80–83% tumor-growth inhibition index scores, irradiation:BNCT ratios of 1:2, and increases in animal life expectancy from 9 to 107 days. (4) Conclusions: Adjustments in dosimetry control, calculation of irradiation doses, and combined use of two10B compounds allowed for BNCT optimization that will be useful in the development of clinical-trial protocols for accelerator-based BNCT.

KW - Accelerator-based neutron source

KW - Animal tumor model

KW - Boron compounds

KW - Boron neutron capture therapy

KW - Boronophenylalanine

KW - Glioblastoma

KW - Sodium borocaptate

UR - http://www.scopus.com/inward/record.url?scp=85119015733&partnerID=8YFLogxK

U2 - 10.3390/biology10111124

DO - 10.3390/biology10111124

M3 - Article

C2 - 34827117

AN - SCOPUS:85119015733

VL - 10

JO - Biology

JF - Biology

SN - 2079-7737

IS - 11

M1 - 1124

ER -

ID: 34642422